| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
|
|
|||||||||
|
|
Oncology: Special SessionsNuclear Oncology Council Young Investigator Award Symposium |
1 National Cancer Center, Korea, Goyang, Gyeonggi-do, South Korea
|
|
80
Objectives: To determine whether FLT-PET could predict treatment response in aggressive non-Hodgkin’s lymphoma (NHL) early assessment of treatment response.
Methods: We recruited 31 patients with CD-20 positive aggressive NHL prospectively (age 56±13 yrs, ranged 31-74 yrs, M:F=20:14) from October 2005 to August 2007. All patients underwent standard R-CHOP regimen. FLT-PET were performed three times before chemotherapy (FLT#1), immediate before the 2nd cycle of chemotherapy (FLT#2), and after complete cycles of chemotherapy (FLT#3). The uptake of FLT were measured semiquantitatively as SUV. The FLT ratio was defined as early ratio using FLT#1 and FLT#2, and late ratio using FLT#1 and FLT#3. Treatment response was assessed after all definitive treatment using conventional imaging, biochemical studies, and FDG PET, using international workshop criteria.
Results: 27 patients responded and 4 patients did not (CR 24, nCR 3, PD 4).The FLT ratios of responder and nonresponder were different (Early ratio: responder 0.30±0.23, nonresponder 0.71±0.31)(Late ratio: responder 0.22±0.23, nonresponder 0.66±0.33 ) Early ratio and late ratio could both predict response accurately and the prediction rate using both was not different (early ratio: 
0.37, sensitivity 77.8%, specificity 100%, AUC 0.898)(late ratio: 0.21, sensitivity 74.1%, specificity 100%, AUC 0.912)
Conclusions: The FLT PET might predict treatment response in NHL. The prediction rate of early period of chemotherapy was not different with that after definitive treatment.
| ||||||||||||||||||||||||||||||||||||||
